The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Durable responses in ICI-refractory or acquired resistance: Phase 2 study of NP-G2-044 combined with anti-PD-1 therapy.
 
Anup Kasi
Consulting or Advisory Role - Cardinal Health; Ipsen
Research Funding - Ability Pharma (Inst); Astellas Pharma (Inst); Bavarian Nordic (Inst); Boundless Bio (Inst); Cardiff Oncology (Inst); Cend Therapeutics (Inst); FibroGen (Inst); Geistlich Pharma (Inst); Novita Pharmaceuticals (Inst); Novocure (Inst); Rafael Pharmaceuticals (Inst); TESARO (Inst)
 
Michael Birrer
Consulting or Advisory Role - AstraZeneca; GlaxoSmithKline; Merck
 
Jason Brown
Honoraria - Johnson & Johnson/Janssen
Consulting or Advisory Role - EMD Serono; Johnson & Johnson/Janssen; Pfizer
Speakers' Bureau - EMD Serono; Merck
Research Funding - Bicycle Therapeutics (Inst); Merck (Inst); Novita Pharmaceuticals (Inst); Pfizer (Inst); Roche/Genentech (Inst)
Travel, Accommodations, Expenses - Johnson & Johnson/Janssen
 
Sanjay Chandrasekaran
Stock and Other Ownership Interests - Lilly
Consulting or Advisory Role - Deciphera; Replimune
Travel, Accommodations, Expenses - Immatics
 
Vincent Chung
Consulting or Advisory Role - Perthera
Research Funding - Merck (Inst)
 
Richard Frank
No Relationships to Disclose
 
Shirish Gadgeel
Consulting or Advisory Role - Abbvie; Arcus Biosciences; Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Daichii-Sanyko; Eisai; Genentech/Roche; Gilead Sciences; Gilead Sciences; Johnson & Johnson/Janssen; Lilly; Merck; Mirati Therapeutics; Pfizer; Regeneron; Takeda
Research Funding - Abbvie (Inst); Amgen (Inst); Arcus Biosciences (Inst); ArriVent Biopharma (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Avistone Biotechnology (Inst); Bayer (Inst); D3 Bio (Inst); Daiichi Sankyo (Inst); Debiopharm Group (Inst); eFFECTOR Therapeutics (Inst); Genentech/Roche (Inst); Genmab (Inst); GRAIL (Inst); Helsinn Therapeutics (Inst); Incyte (Inst); InventisBio (Inst); Iovance Biotherapeutics (Inst); Jacobio (Inst); Janssen Oncology (Inst); Janux Therapeutics (Inst); Kymera (Inst); Merck (Inst); Mirati Therapeutics (Inst); Monte Rosa Therapeutics (Inst); Nimbus Therapeutics (Inst); Novita Pharmaceuticals (Inst); Numab (Inst); Nuvalent, Inc. (Inst); Pfizer (Inst); Regeneron (Inst); Revolution Medicines (Inst); Tango Therapeutics (Inst); Turning Point Therapeutics (Inst); Verastem (Inst)
Travel, Accommodations, Expenses - Merck; Mirati Therapeutics
Other Relationship - AstraZeneca
 
Thomas George
Consulting or Advisory Role - Arbele; Avammune Therapeutics; BillionToOne; Exact Sciences; KAHR Medical; Nihon Medi-Physics; Summit Therapeutics
Research Funding - Amal Therapeutics (Inst); Amgen (Inst); Astellas Pharma (Inst); AstraZeneca/MedImmune (Inst); Bayer (Inst); BillionToOne (Inst); BioMed Valley Discoveries (Inst); Bristol-Myers Squibb (Inst); Deciphera (Inst); Elicio Therapeutics (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Incyte (Inst); Ipsen (Inst); Jounce Therapeutics (Inst); Lilly (Inst); Merck (Inst); OncoC4 (Inst); Regeneron (Inst); Seagen (Inst)
 
Shadia Jalal
Research Funding - AstraZeneca/MedImmune
 
Alberto Mendivil
No Relationships to Disclose
 
Andrew Poklepovic
Speakers' Bureau - Natera
 
Jennifer Segar
No Relationships to Disclose
 
Alexander Spira
Leadership - Next Oncology (Inst)
Honoraria - Abbvie; Abbvie; Abbvie; Amgen; Astellas Pharma; AstraZeneca/MedImmune; Bayer; Bristol-Myers Squibb; CytomX Therapeutics; Janssen Oncology; Merck; Novartis; Prelude Therapeutics; Takeda
Consulting or Advisory Role - Amgen; ArriVent Biopharma; AstraZeneca/MedImmune (Inst); AstraZeneca/MedImmune (Inst); Black Diamond Therapeutics; Blueprint Medicines (Inst); Bristol-Myers Squibb (Inst); Daiichi Sankyo/Astra Zeneca; Gritstone Bio; Gritstone Bio; incyte; Janssen Research & Development; Jazz Pharmaceuticals; Lilly; Merck (Inst); Mersana; Mirati Therapeutics; Novartis; Regeneron; Sanofi; Sanofi; Takeda
Research Funding - Abbvie (Inst); ADC Therapeutics (Inst); ADC Therapeutics (Inst); Alkermes (Inst); Amgen (Inst); ArriVent Biopharma (Inst); Astellas Pharma (Inst); Astex Pharmaceuticals (Inst); AstraZeneca (Inst); Black Diamond Therapeutics (Inst); Blueprint Medicines (Inst); BluPrint Oncology (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); CytomX Therapeutics (Inst); Daiichi Sankyo (Inst); Gritstone Bio (Inst); Ignyta (Inst); Incyte (Inst); Janssen Oncology (Inst); LAM Therapeutics; Loxo (Inst); Loxo (Inst); Macrogenics (Inst); Medikine (Inst); MedImmune (Inst); mersana (Inst); nalo therapeutics (Inst); Novartis (Inst); Plexxikon (Inst); Prelude Therapeutics (Inst); Regeneron (Inst); Revolution Medicines (Inst); Revolution Medicines (Inst); Roche (Inst); Rubius Therapeutics (Inst); Scorpion Therapeutics (Inst); Synthekine (Inst); Synthekine (Inst); Takeda (Inst)
 
Janos Tanyi
Research Funding - Novita Pharmaceuticals (Inst)
 
Hira Yousaf
No Relationships to Disclose
 
Jillian Zhang
Employment - Novita Pharmaceuticals
Leadership - Novita Pharmaceuticals
Stock and Other Ownership Interests - Novita Pharmaceuticals
Consulting or Advisory Role - Novita Pharmaceuticals (I)
Patents, Royalties, Other Intellectual Property - Novita Pharmaceuticals (I)
 
Xin-Yun Huang
Employment - Novita Pharmaceuticals (I)
Leadership - Novita Pharmaceuticals; Novita Pharmaceuticals (I)
Stock and Other Ownership Interests - Novita Pharmaceuticals; Novita Pharmaceuticals (I)
Consulting or Advisory Role - Novita Pharmaceuticals
Research Funding - Novita Pharmaceuticals (Inst)
Patents, Royalties, Other Intellectual Property - Novita has licensed a technology from Cornell University, and Cornell receives milestone payments from Novita. (Inst); Novita has licensed a technology from Cornell University, and Cornell receives milestone payments from Novita. I am a co-inventor on the patents and receive milestone payments from Cornell.
Travel, Accommodations, Expenses - Novita Pharmaceuticals (I)
 
Jose Jimeno
Employment - Novita Pharmaceuticals
Leadership - Novita Pharmaceuticals
Stock and Other Ownership Interests - Novita Pharmaceuticals; Pangaea Oncology; Pharma Mar, S.A. (Madrid, Spain); Promontory Therapeutics
Consulting or Advisory Role - Promontory Therapeutics
Patents, Royalties, Other Intellectual Property - Plitidepsin
 
Frank Tsai
Stock and Other Ownership Interests - Salarius Pharmaceuticals
Consulting or Advisory Role - Aptitude Health; Aptitude Health; Aptitude Health; Tempus
Research Funding - Flynn Foundation (Inst); PhRma Foundation (Inst)
Patents, Royalties, Other Intellectual Property - Clinical trial software.